August 21, 2025 — Leads & Copy — iTolerance, Inc., a biotechnology company focused on regenerative medicines, has appointed Emily Shacter, Ph.D., to its Scientific Advisory Board. Dr. Shacter has supported CMC development for iTolerance since February 2024.
Anthony Japour, CEO of iTolerance, said Dr. Shacter’s experience in biopharmaceutical regulation and development will be instrumental as the company transitions to a clinical-stage company. Dr. Shacter noted iTolerance’s platform technology and its potential to enable therapies without lifelong immunosuppression.
Dr. Shacter served for nearly two decades in the FDA’s Center for Drug Evaluation and Research (CDER), focusing on complex protein therapeutics. Since 2012, she has been an independent consultant advising biotechnology companies. She holds a Ph.D. in Biochemistry from Johns Hopkins University and a B.Sc. in Zoology from the University of Maryland.
iTolerance is developing technologies to enable tissue, organoid, or cell therapy without lifelong immunosuppression, advancing programs using allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes.
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com
Susan Roberts
T:202.779.0929
sr@roberts-communications.com
Source: iTolerance, Inc.
